Published in:
01-12-2020 | Hepatitis B | Review
Description of CRISPR/Cas9 development and its prospect in hepatocellular carcinoma treatment
Authors:
Xiaoling Wu, Weijie Ma, Chengjie Mei, Xi Chen, Ye Yao, Yingyi Liu, Xian Qin, Yufeng Yuan
Published in:
Journal of Experimental & Clinical Cancer Research
|
Issue 1/2020
Login to get access
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignancies today. Patients suffer from HCC since its high malignancy and limited treatment means. With the development of genetic research, new therapeutic strategy comes up in the way of gene editing. Clustered regularly interspaced short palindromic repeat/CRISPR-associated nuclease 9 (CRISPR/Cas9) was discovered as an immune sequence in bacteria and archaea. After artificial transformation and follow-up research, it is widely used as a gene editing tool. In this review, the development of CRISPR/Cas9 is summarized in retrospect. Through the evaluation of novel research in HCC, it is concluded that CRISPR/Cas9 would promote cancer research and provide a new tool for genetic treatment in prospect.